Trial Profile
Treatment of patients with posttransplant lymphoproliferative disorder (PTLD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- Acronyms PTLD-1; PTLD-1/3
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 Planned number of patients changed from 150 to 225.